Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475159 | 1.00 | CYP1A2 (0.72) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL9479735 | 0.85 | CYP1A2 (0.74) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL7263695 | 0.84 | CYP1A2 (1.00) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL7263686 | 0.84 | CYP1A2 (1.00) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL475205 | 0.84 | CYP1A2 (0.72) | CYP1A2TSHRALDH1A1CTSDMEN1 | |
| SCHEMBL475201 | 0.84 | CYP1A2 (0.72) | CYP1A2TSHRALDH1A1CTSDMEN1 | |
| SCHEMBL4726276 | 0.81 | CYP1A2 (0.68) | CYP1A2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL9710218 | 0.81 | CYP1A2 (0.73) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL9710227 | 0.81 | CYP1A2 (0.73) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL4726270 | 0.81 | CYP1A2 (0.68) | CYP1A2TSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023657-B2 | Reversible protein multimers, methods for their production and use | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-07-17 | — | — | US | claimed |
| US-20260146089-A1 | ANTIBODIES TARGETING CD3 AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-28 | — | — | US | disclosed |
| US-12612456-B2 | CD19 antibodies and methods of using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260078340-A1 | SCAFFOLDS WITH STABILIZED MHC MOLECULES FOR IMMUNE-CELL MANIPULATION | UNIV DANMARKS TEKNISKE (DK) | 2026-03-19 | — | — | US | disclosed |
| US-20260042860-A1 | ANTI-CD24 ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4680647-A2 | ANTIBODIES TARGETING CD3 AND USES THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015435-A1 | ANTI-POLYSIALIC ACID ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-12509515-B2 | CD22 antibodies and methods of using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-30 | — | — | US | disclosed |
| US-12497592-B2 | Scaffolds with stabilized MHC molecules for immune-cell manipulation | DANMARKS TEKNISKE UNIVERSITET (DK) | 2025-12-16 | — | — | US | disclosed |
| US-12486323-B2 | Anti-L1-CAM antibodies and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-02 | — | — | US | disclosed |
| EP-1038031-A1 | MASS SPECTROMETRIC METHODS FOR SEQUENCING NUCLEIC ACIDS | SEQUENOM, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-1010008-A2 | MASS SPECTROMETRIC DETECTION OF POLYPEPTIDES | SEQUENOM, INC. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999057318-A2 | INFRARED MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRIC ANALYSIS OF MACROMOLECULES | SEQUENOM, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| EP-0937096-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0937097-A1 | COMPOSITIONS AND METHODS FOR IMMOBILIZING NUCLEIC ACIDS TO SOLID SUPPORTS | SEQUENOM, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999031278-A1 | MASS SPECTROMETRIC METHODS FOR SEQUENCING NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5900481-A | Bead linkers for immobilizing nucleic acids to solid supports | SEQUENOM, INC. (US) | 1999-05-04 | — | — | US | disclosed |
| WO-1999012040-A2 | MASS SPECTROMETRIC DETECTION OF POLYPEPTIDES | SEQUENOM, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1998020019-A1 | COMPOSITIONS AND METHODS FOR IMMOBILIZING NUCLEIC ACIDS TO SOLID SUPPORTS | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| WO-1998020020-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078340-A1 | SCAFFOLDS WITH STABILIZED MHC MOLECULES FOR IMMUNE-CELL MANIPULATION | IL2, MICA, HLA-C | CYP1A2 4527/4885TSHR 3153/4885ALDH1A1 3755/4885 |
| US-20260042860-A1 | ANTI-CD24 ANTIBODIES AND USES THEREOF | CD22, FCGR2A, CD2BP2 | CYP1A2 4256/4885TSHR 2912/4885ALDH1A1 793/4885 |
| US-12612456-B2 | CD19 antibodies and methods of using the same | CD74, CD4, CD2 | CYP1A2 4409/4885TSHR 1127/4885ALDH1A1 4081/4885 |
| US-20260015435-A1 | ANTI-POLYSIALIC ACID ANTIBODIES AND USES THEREOF | VSIG8, CD74, FCGR2A | CYP1A2 4596/4885TSHR 2180/4885ALDH1A1 4437/4885 |
| US-20260146089-A1 | ANTIBODIES TARGETING CD3 AND USES THEREOF | IGLV6-57, IGSF11, VSIG8 | CYP1A2 4508/4885TSHR 398/4885ALDH1A1 4368/4885 |
| US-12509515-B2 | CD22 antibodies and methods of using the same | CD74, CD22, CD2 | CYP1A2 3194/4885TSHR 1597/4885ALDH1A1 3646/4885 |
| US-10023657-B2 | Reversible protein multimers, methods for their production and use | CD4, CD74, CD69 | CYP1A2 4864/4885TSHR 423/4885ALDH1A1 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.